Bo Wang, MD, discusses the positive outcomes for divarasib vs other KRAS G12C inhibitors in non–small cell lung cancer.
Bo Wang, MD
Advertisement
Articles by Bo Wang, MD
Advertisement
Latest Updated Articles
Next-Generation Design Drives Divarasib Gains in Krascendo 1 TrialNovember 9th 2026
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Accepts sNDA for Gedatolisib in PIK3CA-Mutated HR+/HER2– Breast Cancer
2
Imneskibart Regimens Show Activity in ICI-Refractory Melanoma, NSCLC
3
Comparing Treatment Approaches in Second-Line Metastatic ccRCC
4
LITESPARK-011 Raises Questions About RCC Treatment Sequencing
5